Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population

NCT02661490 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

Norovirus

Interventions

BIOLOGICAL: Norovirus GI.1/GII.4 Bivalent VLP Vaccine
DRUG: 0.9% sodium chloride (saline)
BIOLOGICAL: Norovirus GI.1/GII.4 Bivalent VLP Vaccine

Sponsor

Takeda